IPO - Profile


We are a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Our lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. There is no approved medical treatment currently available to specifically alleviate the symptoms of cannabinoid overdose and we are not aware of any competing products that are further along in the development process More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$7.00 3,000,000 Positive High 43.83%

Offering Team

  • Legal counsel
  • Olshan Frome Wolosky LLP
  • Auditors
  • EisnerAmper LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 06 May, 2021

Offer 07 May, 2021

Look Ahead

Lock Up Expiry Nov 07, 2021

IPO Terms

Offer Price $7.00
Offer Size 3M

Market Sentiments

Stock Price